Clinical Cases

Introducing real hemophilia A patients* who chose ALTUVIIIO

Unlock Factor VIII levels that stay higher for longer (>40% for most of the week in adults)^1-3

Dive into these hemophilia A patients cases to learn about how switching to ALTUVIIIO prophylaxis helped them manage their breakthrough bleeds and how their lives are different after making the switch.

Meet Peter

A 32 year old reverend with severe hemophilia A previously on prophylaxis therapy.

View Peter's Case

Meet Otis

A 43 year old who works loading trucks and previously treated his moderate hemophilia A with an on-demand therapy.

View Otis' Case

Meet Noah

A 2 year old who was diagnosed with severe hemophilia A at birth due to a de novo mutation and was treating with prophylaxis therapy.

View Noah's Case

^* Patient stories adapted from actual ALTUVIIIO patients. Names and photos have been changed to protect patient identity.

Indication

ALTUVIIIO^® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

Routine prophylaxis to reduce the frequency of bleeding episodes
On-demand treatment & control of bleeding episodes
Perioperative management of bleeding

Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions

Allergic-type hypersensitivity reactions, including anaphylaxis, may occur with ALTUVIIIO. Allergic-type hypersensitivity reactions were not reported in the clinical trials. Advise patients to discontinue use of ALTUVIIIO if hypersensitivity symptoms occur and contact a physician and/or seek immediate emergency care.
Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.

Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Please see full Prescribing Information.

Learn more about Sanofi’s commitment to fighting counterfeit drugs.

Indication

Important Safety Information

References: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 2. von Drygalski A, et al. N Engl J Med. 2023;388(4):310-318. 3. Chhabra ES, et al. Blood. 2020;135(17):1484-1496.

Introducing real hemophilia A patients* who chose ALTUVIIIO

Unlock Factor VIII levels that stay higher for longer (>40% for most of the week in adults)1-3

Dive into these hemophilia A patients cases to learn about how switching to ALTUVIIIO prophylaxis helped them manage their breakthrough bleeds and how their lives are different after making the switch.

Meet Peter

Meet Otis

Meet Noah

Indication

Limitation of Use

Important Safety Information

Contraindications

Warnings and Precautions

Adverse Reactions

Indication

Important Safety Information

Unlock Factor VIII levels that stay higher for longer (>40% for most of the week in adults)^1-3